Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $22.7 million.

  • Conmed's Change in Receivables rose 8283.06% to $22.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 million, marking a year-over-year increase of 4583.08%. This contributed to the annual value of $2.4 million for FY2025, which is 4583.08% up from last year.
  • According to the latest figures from Q4 2025, Conmed's Change in Receivables is $22.7 million, which was up 8283.06% from -$9.2 million recorded in Q3 2025.
  • Conmed's 5-year Change in Receivables high stood at $22.7 million for Q4 2025, and its period low was -$19.0 million during Q1 2025.
  • For the 5-year period, Conmed's Change in Receivables averaged around $3.3 million, with its median value being $1.9 million (2023).
  • As far as peak fluctuations go, Conmed's Change in Receivables surged by 1257852.76% in 2023, and later plummeted by 219074.89% in 2025.
  • Conmed's Change in Receivables (Quarter) stood at $19.0 million in 2021, then plummeted by 157.16% to -$10.9 million in 2022, then soared by 183.14% to $9.1 million in 2023, then soared by 36.97% to $12.4 million in 2024, then soared by 82.83% to $22.7 million in 2025.
  • Its Change in Receivables stands at $22.7 million for Q4 2025, versus -$9.2 million for Q3 2025 and $7.8 million for Q2 2025.